The Fast 50’s were presented to the top 50 fastest growing companies in the Greater Manchester area based on annual growth over a three year period.
The event was held at Old Trafford, the home of Manchester United Football Club.
Torsten Schanze, Operations Manager of Nanoco Technologies, received the award on behalf of the company. In a statement he pointed out that: “This accolade recognizes the tremendous speed at which Nanoco has developed over the past couple of years. The move into new and purpose built facilities, the recent expansion of those facilities, the flotation on the stock market and the number of new hires show that the company is moving in the right direction, especially in these difficult economic times.”
Manchester-based water treatment company Arvia Technology has won the Institution of Engineering and Technology’s (IET) North West Innovation Award.
The University of Manchester spin-out offers a low carbon, chemical and waste free process for the onsite treatment and recycling of industrial waste water.
The technology captures pollutants using Nyex, Arvia’s patented material and then destroys them by applying a low-power electric current.
Arvia says this combined function is an innovation first and also 90 per cent cheaper than conventional techniques.
Chair of the judging panel, Unilver’s Malcolm Sarstedt said: “We were very impressed with the number and consistent high standard of entries – demonstrating that the north west of England is still a hot bed of innovation.
“Sustainability is now a key driver for change, and Arvia has not only achieved effective, sustainable water treatment, but also significant cost benefits compared to competing technologies. This is an excellent example of the sort of innovation that industry is looking to apply.”
Arvia’s chief executive Martin Keighley said: “We’re absolutely delighted to win this award, particularly as entrants were drawn from all industries. For Arvia to be recognised in the face of such stiff competition is a great achievement.”
Keighley recently attended the launch of the Government’s new National Innovation Investment Fund at the London Stock Exchange.
Arvia, whose customers include water utility and ground water remediation companies, was one of only four companies invited to attend and offer their vision for the future of high-tech venture capital investment in the UK to an audience which included science minister Lord Drayson and business secretary Lord Mandelson.
Source: Crains Manchester Business
UMIC are celebrating ten years of successful biotechnology incubation and growth with a
major event involving industry, government and investor delegates on Wednesday 23rd September 2009. Speakers include Sir William Castell, Chairman of the Wellcome Trust and ex-CEO of Amersham plc .
The event will also celebrate the 5th anniversary of UMIP and UMIC.
Roundtable discussions on financing & investment, drug development, and national policymaking will be led by experienced local professionals who have ‘been there, done that’.
Finally a showcase exhibition throughout the event will highlight Northwest biotech, UMIC partners, collaborators, spin-out companies and research projects within The University of Manchester.
We anticipate strong delegate representation from government, research councils, industry and academia.
Please visit the UMIC webite for more information www.umic.co.uk/anniversary_event/
Manchester, England, 6th July 2009 – F2G Limited, the Manchester UK based antifungal drug discovery and development company, today announced the initiation of a Phase I clinical study of FG3622, the company’s lead antifungal drug candidate.
The Phase 1 trial is a randomised, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of FG3622. 100 healthy volunteers will be enrolled in the trial which will evaluate single as well as multiple ascending doses of FG3622 which will be administered orally. This clinical trial is the first-in-human study in the global development of FG3622 and will be conducted in the UK.
FG3622 is the first of a new generation of novel class systemic antifungal agents active by both oral and intravenous administration to enter the clinic. The mechanism of action, discovered by scientists at F2G, involves the selective inhibition of a fungal enzyme and is completely distinct from any other class of marketed antifungal agent. The compound displays highly potent activity against a wide range of clinically significant moulds including the common pathogen Aspergillus fumigatus which is the leading cause of Invasive Aspergillosis, a serious, debilitating disease associated with very high mortality rates despite current therapy options.
The incidence of serious life threatening fungal infections has increased steadily over the last 20 years as a result of an increase in the susceptible immunosuppressed patient population. There is a limited choice of antifungals to treat systemic infections and these are currently represented by only three classes of compound. Resistance is becoming an increasing problem, particularly amongst the azole class. The value of the systemic antifungal market rose to USD 3 billion in 2007 and is forecast to grow substantially in the next 7 years.
Mr Shane Kelly, Chief Executive of F2G said “The progress of the FG3622 program represents a tremendous milestone for our scientists and their approach to antifungal drug discovery. Based on its unique mechanism of action and compelling preclinical data, we are hopeful that FG3622 will offer a major advance in antifungal therapy.”
Dr Anthony Kennedy, Chief Scientific and Development Officer added “The first in man trial is an important step for F2G in the development of FG3622 and will provide us with the data needed to design and expedite clinical studies in patients.”
Dr Thomas Tscherning, Partner at BankInvest Biomedical Venture and Chairman of the F2G Board of Directors, commented “This is a significant achievement for F2G, as initiation of this first trial offers F2G the opportunity to demonstrate the broad clinical potential of a new class of antifungal therapeutics. There is a clear clinical need for new agents to treat systemic fungal infections and we believe FG3622 presents a very promising new approach to treating these serious and life-threatening conditions.”
About F2G Ltd:
Based in Manchester, UK, F2G Ltd is dedicated to the discovery and development of new and clinically superior drug classes to treat life-threatening systemic fungal infections in at-risk patient populations. The antifungal market is currently estimated at over 6 billion dollars annually and is growing steadily year on year. Market growth is expected to increase with the emergence of new clinical indications in allergies and asthma.
The company has impressive internal capabilities, employing a core team of scientists with a unique understanding of the antifungal arena, supported by an experienced management team. F2G operates a flexible business model, building value through the development of a balanced portfolio of antifungal assets across multiple validated TPPs.
For more information visit www.f2g.com
Paul Strzelecki has been appointed Honorary Visiting Professor at The University of Manchester, at the School of Electrical and Electronic Engineering.
Paul is an alumnus of the School, a Fellow of the Institute of Engineering and Technology and a Fellow of the Chartered Institute of Marketing.
Paul will have an enterprise focus to his role. This will include assisting the School with industrial contacts, helping researchers identify and commercialise intellectual property, through spin-out companies and licensing, and lecturing students in enterprise subjects relating to the electronics industry.
Currently Managing Director of Yorkville Advisors UKLLP offering a fund investing in global public companies, Paul has had a successful corporate career in the world of semiconductor and electronics including a European Vice President at Motorola before becoming a successful internet and mobile communications entrepreneur and a venture capitalist. Paul has also been an adviser to Manchester United FC.
The School is one of the largest electrical engineering schools in the UK and highly rated for its “Research Power” and is headed by Professor Andy Gibson. “The School has a good history of working with industry and I am delighted that Paul will be assisting with our goals and helping extend our international reach and collaborations across the spectrum of our innovative research activities “he said.
Paul is enthusiastic about his role. “Electrical technology continues to change the world, at work and play at an ever increasing rate” he said, “ yet there are still huge challenges to be met”. “Electrical engineering can provide solutions to climate change and reduction and changes in energy consumption.”
Paul is excited about one of the School’s expertise areas, where it leads the world: agri – electronics, which uses electrical and electronic technology to improve farming yields and to reduce waste in the food supply change. This links with another area where the University is taking a lead – sustainable consumption.
“It’s an honour to be asked to contribute to the world class team in Manchester. If we can create new businesses that literally change the world from the research activity and contribute to the UKs industrial future it will be a thrilling journey.
Last year, Paul was appointed to the Strategy Advisory Board of the UMIP Premier Fund (UPF), a unique fund dedicated to assisting the financing of spin-out companies from the University.